PolarityTE, Inc. announced that Richard Hague will join as the company's Chief Operating Officer on April 8, 2019. Mr. Hague brings to PolarityTE experience in many aspects of corporate development and operations from his more than 30-year career in the biotechnology industry, including launching a variety of autologous cell and tissue therapies. Current COO Ned Swanson, MD, will continue on as PolarityTE's Chief Translational Medicine Officer. Mr. Hague joins PolarityTE from Anika Therapeutics where he served as Chief Commercial Officer, overseeing the launch of a novel device-drug combination injection therapy for osteoarthritis.